Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Medical Health Institute

Aurelius Health Group
Graded #311

Higher grade

vs+7.5
Medical Health Institute
Graded #469

Lower grade

The verdict

Aurelius Health Group takes it — 60.8/100 to 53.3/100.

Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +9
54
45
Dose & formulationAurelius Health Group +12
52
40
Clinical oversightAurelius Health Group +7
76
69
Labs & monitoringAurelius Health Group +11
63
52
FulfillmentMedical Health Institute +6
61
67
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barMedical Health Institute · right bar

The numbers

MetricAurelius Health GroupMedical Health Institute
WeighScore60.8/10053.3/100
GradeCC
Scorecard rank#311#469
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #311 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • The advertised $89 is a first-month new-patient rate; every month after it is $199
  • This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
  • No state count is published, only 'most US states', confirmed at intake
  • The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
  • Compounded tirzepatide is not an FDA-approved finished product
Medical Health Institute

Graded #469 · C

Strengths

  • Operating entity disclosed: Medical Health Institute, LLC, with full Pinecrest, FL address and phone
  • Named medical director (Amy Wecker, MD) plus four more named clinicians on the about page
  • Three care pathways with starting-price anchors: $99 TRT / $129 peptides / $149 weight-loss
  • LegitScript Certified with a footer verification link
  • HIPAA compliance claimed

Where it loses points

  • GLP-1 medication options (semaglutide vs tirzepatide; compounded vs brand) not shown — gated behind the intake funnel
  • Pharmacy partner not named — only generic 'FDA-regulated facilities' language
  • State availability not disclosed
  • Several subpages (/weight-loss, /pricing, /products, /faq) returned server errors during verification
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard